Effect of anticancer drugs on production of transforming growth factor B and expression of p53 and Bcl-2 proteins by MCF-7 and T47D cell lines of human breast carcinoma

Experimental Oncology

Volumn 30, Issue 1, 2008, Pages 35-41

  Stoika, R S ^a   Yakymovych, I A ^a   Kashchak, N I ^a   Boyko, M M ^a   Korynevska, A V ^a   Klyuchyvska, O Yu ^a   Shafranska, G I ^a   Yakymovych, M Ya ^a   Zhylchuk, V Ye ^b   Kudryavets, Yu Y ^c   Vorontsova, A L ^c  

^a INSTITUTE OF CELL BIOLOGY   (Ukraine)

^b Rivne Regional Oncological Clinics   (Ukraine)

^c R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Anticancer drugs; Apoptosis; Bcl 2; Human breast carcinoma; MCF 7 and T47D cell lines; p53; Transforming growth factor

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; PROTEIN BCL 2; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; VINCRISTINE;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DOXORUBICIN; HUMANS; JURKAT CELLS; METHOTREXATE; MICE; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE;

EID: 42049083781     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Young RC. In: Drug Resistance in Cancer Therapy. Kluwer, Dordrecht, 1989: 1-26.
2. Couture L, Nash JA Turgeon J. The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Parmacol Rev 2006; 58: 244-58.
3. Levina W, Drobchenko EA, Shabalina EV. A new human breast carcinoma cell line resistant to DNA-damaging drugs. ATLA (Alternatives to Laboratory Animals) 2004; 32: 391-9.
4. Stoika R, Yakymovych M, Souchelnitskiy S, et al. Potential rol of transforming growth factor b1 in drug resistance of tumor cells. Acta Biochim Polon 2003; 50: 497-508.
5. Filyak Ye, Filyak O, Stoika S. Transforming growth factor beta-1 enhances cytotoxic effect of doxorubicin in human lung adenocarcinoma cells of A549 line. Cell Biol Int 2007; 31: 851-5.
6. Souchelnytskyi S. Transforming growth factor-β signaling and its role in cancer. Exp Oncol 2002; 24: 3-12.
7. Chorna IV, Datsyuk LO, Stoika RS. Expression of Bax, Bad and Bcl-2 proteins under X-radiation effect towards human breast carcinoma MCF-7 cells and their doxorubicin-resistant derivatives. Exp Oncol 2005; 27: 196-201.
8. Fridenberg WR, Salzman SA, Phan SM, et al. Transforming growth factor-beta and multidrug resistance in chronic lymphocytic leukemia. Med Oncol 1999; 16: 110-8.
9. Nakao A, Imamura T, Souchelnytskyi S, et al. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 1997; 16: 5353-62.
10. 1 in patients with breast cancer. Arch Surg 2001; 136: 937-40.
11. 1 plasma level in patients with lung cancer: potential mechanisms. Eur J Clin Invest 2002; 32: 193-8.
12. Takanami I, Imamura T, Hashizume T, et al. Transforming growth factor-beta 1 as a prognostic factor in pulmonary adenocarcinoma. J Clin Pathol 1994; 47: 1098-100.
13. Wolff JM, Fandel T, Borchers H, et al. Transforming growth factor-β1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia. Br J Urol 1998; 81: 403-5.
14. Ford J, Smith S, Luo JC, et al. Serum growth factors and oncoproteins in firefighters. Occup Med (Lond) 1992; 42: 39-42.
15. Teicher BA. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 2001; 20: 133-43.
16. Bennett WP, Deiry WS, Rush WL, et al. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res 1998; 4: 1499-506.
17. Boldrini L, Calcinai A, Samaritani E, et al. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma, putative relation with BCL-2-mediated neovascularization. Br J Cancer 2000; 83: 480-6.
18. Fisher JR, Darjes H, Lahm H, et al. Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines. Eur J Cancer 1994; 30A: 2125-9.
19. Lagadec PF, Saraya KA, Balkwill FR. Human small-cell lung-cancer cells are cytokine-resistant but NK/LAK-sensitive. Int J Cancer 1991; 48: 311-7.
20. Segal-Bendirdjian E, Mannone L, Jacquemin-Sablon A. Alteration in p53 pathway and defect in apoptosis contribute independently to cisplatin-resistance. Cell Death Differ 1998; 5: 390-400.